Business Context and Reporting Period
Inhibikase Therapeutics, Inc. (IKT) filed this Form 8-K on July 25, 2022, regarding a regulatory notice from The Nasdaq Stock Market LLC. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Atlanta, Georgia.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on stock listing compliance.
Material Changes
The Company received a Minimum Bid Price Notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2). The closing bid price of the Company's Common Stock remained below $1.00 per share for the last 30 consecutive business days prior to the notice date.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted an initial 180-day compliance period ending January 23, 2023, to regain compliance.
- Remediation Path: Compliance is achieved if the closing bid price remains at or above $1.00 per share for a minimum of 10 consecutive business days within the compliance period.
- Delisting Risk: If compliance is not met, Nasdaq may grant a second 180-day period if the Company meets other listing standards and notifies Nasdaq of its intent to cure. Failure to regain compliance ultimately results in delisting.
- Appeal Rights: The Company retains the right to appeal a delisting determination to a Nasdaq hearings panel.
- Uncertainty: Management states there can be no assurance that the Company will regain compliance or maintain other listing requirements.
Investor Verification Checklist
- Verify the current closing bid price of IKT stock relative to the $1.00 threshold.
- Monitor the Company's progress toward achieving 10 consecutive days of trading at or above $1.00 before January 23, 2023.
- Review subsequent filings for any announcements regarding a second compliance period or delisting notices.
- Confirm the Company's status regarding other Nasdaq listing standards (e.g., market value of publicly-held shares) in case a second compliance period is required.